Inhibrx (NASDAQ:INBX – Get Free Report) announced its quarterly earnings data on Monday. The company reported ($3.09) earnings per share for the quarter, missing the consensus estimate of ($2.88) by ($0.21), Zacks reports. The company had revenue of $0.10 million during the quarter.
Inhibrx Stock Down 1.1 %
NASDAQ INBX opened at $13.94 on Tuesday. The firm’s fifty day moving average price is $13.33 and its two-hundred day moving average price is $14.67. Inhibrx has a fifty-two week low of $10.80 and a fifty-two week high of $35.42.
Wall Street Analysts Forecast Growth
Separately, JMP Securities reissued a “market perform” rating on shares of Inhibrx in a report on Wednesday, January 22nd.
Inhibrx Company Profile
Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.
Featured Stories
- Five stocks we like better than Inhibrx
- What is diluted earnings per share (Diluted EPS)?
- Southwest Airlines Could Triple From Here—Here’s How
- How to Buy Cheap Stocks Step by Step
- Salesforce: An Early AI Opportunity With Long-Term Potential
- What is Put Option Volume?
- Taiwan Semiconductor Valuation: How Realistic Is the Price?
Receive News & Ratings for Inhibrx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inhibrx and related companies with MarketBeat.com's FREE daily email newsletter.
